Abstract: The present disclosure provides for, and includes, pharmaceutical formulations comprising an MANP peptide, methods of preparing such formulations, and uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present disclosure further provides for, and includes, methods for increasing the stability by a peptide formulation and for reducing aggregation during production of a peptide formulation.

Abstract: The present disclosure provides for, and includes, pharmaceutical formulations comprising an MANP peptide, methods of preparing such formulations, and uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present disclosure further provides for, and includes, methods for increasing the stability by a peptide formulation and for reducing aggregation during production of a peptide formulation.

Abstract: Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).

Abstract: Non-invasive, outcome-confirmed renal denervation procedures include assessments performed before, during, and after an ablation procedure. Stimulation operations can be performed by ultrasound application apart from ablation and/or heating operations to determine the presence and/or condition of a renal nerve in a targeted region. Consistent nerve ablation can be achieved (e.g., in a spontaneous hypertensive patient) by assessing the pathophysiology of renal denervation via (1) reduction of blood pressure and/or (2) kidney and serum norepinephrine concentration.

Abstract: MRI-guided high-intensity focused ultrasound (“HIFU”) therapy can be used to ablate sympathetic nerves near the renal arteries. Such therapy may employ a HIFU device that includes an ultrasound transducer and an expandable reservoir that includes a first surface configured to conform to a surface anatomy of a patient and a port in fluid communication with a fluid source. The expandable reservoir can be configured to change a size in a dimension by inflating or deflating the expandable reservoir. Such a device may be used in connection with an MRI device that includes a support portion configured to conform to the surface anatomy of the patient and defining a first window configured to receive the ultrasound transducer for targeting tissue. The MRI device can include radiofrequency coil arrays embedded throughout to the support portion to monitor the therapy.